Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 7707 results

  1. Paclitaxel + XR17 (Paclical) with carboplatin for ovarian cancer TS ID 5462

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Riluzole oral film for treating amyotrophic lateral sclerosis TS ID 11779

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Gantenerumab for treating early Alzheimer's disease TS ID 10668

    Awaiting development [GID-TA11072] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over TS ID 10392

    Awaiting development [GID-TA11085] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 TS ID 10766

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Teduglutide for treating short bowel syndrome in babies 4 to 12 months [TS ID 10755]

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

    Awaiting development [GID-TA10774] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Rezafungin for untreated invasive candidiasis TS ID 10768

      Status ...

    Technology appraisal guidance
    Topic selection

  9. Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]

    Awaiting development [GID-TA11040] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma

    In development [GID-IPG10067] Expected publication date: TBC

    Interventional procedures guidance
    In development

  11. Pernicious anaemia

    Awaiting development [GID-QS10130] Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Abdominal aortic aneurysm

    Awaiting development [GID-QS10035] Expected publication date: TBC

    Quality standard
    Awaiting development

  13. Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)

    Awaiting development [GID-TA10426] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Tinnitus

    Awaiting development [GID-QS10091] Expected publication date: TBC

    Quality standard
    Awaiting development

  15. Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

    In development [GID-TA10446] Expected publication date: TBC

    Technology appraisal guidance
    In development